GNAI2

Guanine nucleotide-binding protein G(i) subunit alpha-2 · P04899 · GNAI2 on Sugi Atlas →

489 patent compounds predicted against GNAI2, 426 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Alisertib Alisertib (SCHEMBL855823) 1.00 1/20
Alisertib Alisertib (SCHEMBL29354333) 1.00 1/20
Alisertib Alisertib (SCHEMBL29437869) 1.00 1/20
Alisertib Alisertib (SCHEMBL29720486) 1.00 1/20
Alisertib Alisertib (SCHEMBL29750414) 1.00 1/20
Alisertib Alisertib (SCHEMBL854553) 0.98 1/20
Alisertib Alisertib (SCHEMBL15263514) 0.98 1/20
Alisertib Alisertib (SCHEMBL14125416) 0.97 1/20
SCHEMBL2389378 SCHEMBL2389378 0.94 1/20
SCHEMBL2389355 SCHEMBL2389355 0.89 1/20
SCHEMBL2392579 SCHEMBL2392579 0.89 1/20
SCHEMBL20214913 SCHEMBL20214913 0.89 1/20
SCHEMBL12454978 SCHEMBL12454978 0.89 1/20
SCHEMBL26005084 SCHEMBL26005084 0.89 1/20
SCHEMBL2386771 SCHEMBL2386771 0.87 1/20
Alisertib Alisertib (SCHEMBL854552) 0.86 1/20
Alisertib Alisertib (SCHEMBL29664627) 0.86 1/20
Alisertib Alisertib (SCHEMBL30405892) 0.86 1/20
SCHEMBL12054412 SCHEMBL12054412 0.86 1/20
SCHEMBL10072296 SCHEMBL10072296 0.86 1/20

Clinical trials — most relevant to GNAI2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency PHASE3ACTIVE_NOT_RECRUITING
A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II PHASE2/PHASE3RECRUITING
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a) PHASE2NOT_YET_RECRUITING
PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright Syndrome PHASE1/PHASE2COMPLETED
Study on the Carcinogenesis of Gα12 in Oral Cancer, and the Treatment of Oral Cancer Using Ga12 Inhibitor. nanUNKNOWN
Adrenocorticotropic Hormone (ACTH) Stimulation and G Protein nanCOMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing nanCOMPLETED
NGLY1 Natural History nanCOMPLETED
Multicenter Phenotype-Genotype Analysis of Vascular Stains to Optimize Treatment Utilizing Optical Coherence Tomography nanACTIVE_NOT_RECRUITING
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM) nanCOMPLETED
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity nanNOT_YET_RECRUITING
Use of miRNAs in Growth Hormone Deficiency (GHD) nanUNKNOWN
GNAO1 Natural History Study nanUNKNOWN
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors nanWITHDRAWN
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
Effect of Intraperitoneal Bupivacaine with Dexmedotomidine or Fentanyl for Post-Operative Analgesia Following Laparoscopy in Pediatric Patients nanNOT_YET_RECRUITING
Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome nanACTIVE_NOT_RECRUITING
Study of Adrenal Gland Tumors nanCOMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH) nanCOMPLETED
Brain Receptors in Sympathetic Nervous System Regulation nanCOMPLETED
Biomarker for Sanfilippo Type A-B-C-D Disease (BioSanfilippo) nanWITHDRAWN
The Application of 68Ga-Pentixafor Alongside 68Ga-FAPI-04 PET/MR for Assessing Primary Aldosteronism. nanNOT_YET_RECRUITING
Genetic Analysis of Gray Platelet Syndrome nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GNAI2 binder may also engage these)

ProteinNameSimilarity
P38402 1.000 P38402 →
P08752 1.000 P08752 →
GNAI3 Guanine nucleotide-binding protein G(i) subunit alpha-3 1.000 landscape →
Q60397 1.000 Q60397 →
Q5RAD4 1.000 Q5RAD4 →
Q4R592 1.000 Q4R592 →
Q9DC51 1.000 Q9DC51 →
GNAI1 Guanine nucleotide-binding protein G(i) subunit alpha-1 1.000 landscape →
P38400 1.000 P38400 →
P51877 1.000 P51877 →
P51876 1.000 P51876 →
P04897 1.000 P04897 →
P0C7Q4 1.000 P0C7Q4 →
P08753 1.000 P08753 →
P50147 1.000 P50147 →
P30682 1.000 P30682 →
P10825 1.000 P10825 →
P38403 1.000 P38403 →
P30676 1.000 P30676 →
P38401 1.000 P38401 →
O13055 1.000 O13055 →
P59216 1.000 P59216 →
P16378 1.000 P16378 →
GNAO1 Guanine nucleotide-binding protein G(o) subunit alpha 1.000 landscape →
Q00743 1.000 Q00743 →
P20612 1.000 P20612 →
P18872 1.000 P18872 →
P10824 1.000 P10824 →
P04695 1.000 P04695 →
P08239 1.000 P08239 →